Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis

competing risks and multistate model

Salvatore Petta, Vito Di Marco, Savino Bruno, Marco Enea, Vincenza Calvaruso, Vincenzo Boccaccio, Sonia Rossi, Antonio Craxì, Calogero Cammà

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background & Aims: No published study to date has provided a careful analysis of the effects of a sustained viral response (SVR) on the outcomes of patients with compensated hepatitis C virus (HCV)-related cirrhosis in relation to the degree of portal hypertension. Therefore, we estimated the impact of achieving SVR on disease progression, hepatocellular carcinoma (HCC) development and mortality in a large cohort of HCV patients with cirrhosis with or without oesophageal varices (OVs) at the start of antiviral therapy. Methods: A total of 535 Caucasian patients were prospectively recruited to this study. All patients had a clinical or histological diagnosis of compensated HCV-related cirrhosis and underwent interferon-based therapy. Competing risks and a multistate model were analysed according to the presence or absence of OVs at baseline. Results: Compared to patients without SVR, a greater proportion of patients who achieved SVR showed no liver disease progression after 10 years (36.3% vs. 61.3% of patients without baseline OVs; 29.6% vs. 64.3% of patients with baseline OVs). Achievement of SVR was significantly associated with reduced occurrence rates of de-novo OVs, hepatic decompensation and HCC. Compared to patients without SVR, patients with SVR had lower likelihoods of liver-related death at 10 years (20.6% vs. 10.3% of patients without baseline OVs; 50.5% vs. 21.8% of patients with baseline OVs). Conclusions: In patients with compensated HCV-related cirrhosis with or without OVs at baseline, SVR is associated with reduced disease progression and liver-related mortality.

Original languageEnglish
Pages (from-to)1765-1773
Number of pages9
JournalLiver International
Volume36
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Hepacivirus
Fibrosis
Esophageal and Gastric Varices
Viruses
Disease Progression
Hepatocellular Carcinoma
Liver
Mortality
Portal Hypertension
Interferons
Antiviral Agents
Liver Diseases

Keywords

  • cirrhosis
  • HCV
  • multistate
  • SVR

ASJC Scopus subject areas

  • Hepatology

Cite this

Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis : competing risks and multistate model. / Petta, Salvatore; Di Marco, Vito; Bruno, Savino; Enea, Marco; Calvaruso, Vincenza; Boccaccio, Vincenzo; Rossi, Sonia; Craxì, Antonio; Cammà, Calogero.

In: Liver International, Vol. 36, No. 12, 01.12.2016, p. 1765-1773.

Research output: Contribution to journalArticle

Petta, S, Di Marco, V, Bruno, S, Enea, M, Calvaruso, V, Boccaccio, V, Rossi, S, Craxì, A & Cammà, C 2016, 'Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model', Liver International, vol. 36, no. 12, pp. 1765-1773. https://doi.org/10.1111/liv.13156
Petta, Salvatore ; Di Marco, Vito ; Bruno, Savino ; Enea, Marco ; Calvaruso, Vincenza ; Boccaccio, Vincenzo ; Rossi, Sonia ; Craxì, Antonio ; Cammà, Calogero. / Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis : competing risks and multistate model. In: Liver International. 2016 ; Vol. 36, No. 12. pp. 1765-1773.
@article{76587598ca6243cc8798f86aaf9a8f9d,
title = "Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model",
abstract = "Background & Aims: No published study to date has provided a careful analysis of the effects of a sustained viral response (SVR) on the outcomes of patients with compensated hepatitis C virus (HCV)-related cirrhosis in relation to the degree of portal hypertension. Therefore, we estimated the impact of achieving SVR on disease progression, hepatocellular carcinoma (HCC) development and mortality in a large cohort of HCV patients with cirrhosis with or without oesophageal varices (OVs) at the start of antiviral therapy. Methods: A total of 535 Caucasian patients were prospectively recruited to this study. All patients had a clinical or histological diagnosis of compensated HCV-related cirrhosis and underwent interferon-based therapy. Competing risks and a multistate model were analysed according to the presence or absence of OVs at baseline. Results: Compared to patients without SVR, a greater proportion of patients who achieved SVR showed no liver disease progression after 10 years (36.3{\%} vs. 61.3{\%} of patients without baseline OVs; 29.6{\%} vs. 64.3{\%} of patients with baseline OVs). Achievement of SVR was significantly associated with reduced occurrence rates of de-novo OVs, hepatic decompensation and HCC. Compared to patients without SVR, patients with SVR had lower likelihoods of liver-related death at 10 years (20.6{\%} vs. 10.3{\%} of patients without baseline OVs; 50.5{\%} vs. 21.8{\%} of patients with baseline OVs). Conclusions: In patients with compensated HCV-related cirrhosis with or without OVs at baseline, SVR is associated with reduced disease progression and liver-related mortality.",
keywords = "cirrhosis, HCV, multistate, SVR",
author = "Salvatore Petta and {Di Marco}, Vito and Savino Bruno and Marco Enea and Vincenza Calvaruso and Vincenzo Boccaccio and Sonia Rossi and Antonio Crax{\`i} and Calogero Camm{\`a}",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/liv.13156",
language = "English",
volume = "36",
pages = "1765--1773",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "12",

}

TY - JOUR

T1 - Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis

T2 - competing risks and multistate model

AU - Petta, Salvatore

AU - Di Marco, Vito

AU - Bruno, Savino

AU - Enea, Marco

AU - Calvaruso, Vincenza

AU - Boccaccio, Vincenzo

AU - Rossi, Sonia

AU - Craxì, Antonio

AU - Cammà, Calogero

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background & Aims: No published study to date has provided a careful analysis of the effects of a sustained viral response (SVR) on the outcomes of patients with compensated hepatitis C virus (HCV)-related cirrhosis in relation to the degree of portal hypertension. Therefore, we estimated the impact of achieving SVR on disease progression, hepatocellular carcinoma (HCC) development and mortality in a large cohort of HCV patients with cirrhosis with or without oesophageal varices (OVs) at the start of antiviral therapy. Methods: A total of 535 Caucasian patients were prospectively recruited to this study. All patients had a clinical or histological diagnosis of compensated HCV-related cirrhosis and underwent interferon-based therapy. Competing risks and a multistate model were analysed according to the presence or absence of OVs at baseline. Results: Compared to patients without SVR, a greater proportion of patients who achieved SVR showed no liver disease progression after 10 years (36.3% vs. 61.3% of patients without baseline OVs; 29.6% vs. 64.3% of patients with baseline OVs). Achievement of SVR was significantly associated with reduced occurrence rates of de-novo OVs, hepatic decompensation and HCC. Compared to patients without SVR, patients with SVR had lower likelihoods of liver-related death at 10 years (20.6% vs. 10.3% of patients without baseline OVs; 50.5% vs. 21.8% of patients with baseline OVs). Conclusions: In patients with compensated HCV-related cirrhosis with or without OVs at baseline, SVR is associated with reduced disease progression and liver-related mortality.

AB - Background & Aims: No published study to date has provided a careful analysis of the effects of a sustained viral response (SVR) on the outcomes of patients with compensated hepatitis C virus (HCV)-related cirrhosis in relation to the degree of portal hypertension. Therefore, we estimated the impact of achieving SVR on disease progression, hepatocellular carcinoma (HCC) development and mortality in a large cohort of HCV patients with cirrhosis with or without oesophageal varices (OVs) at the start of antiviral therapy. Methods: A total of 535 Caucasian patients were prospectively recruited to this study. All patients had a clinical or histological diagnosis of compensated HCV-related cirrhosis and underwent interferon-based therapy. Competing risks and a multistate model were analysed according to the presence or absence of OVs at baseline. Results: Compared to patients without SVR, a greater proportion of patients who achieved SVR showed no liver disease progression after 10 years (36.3% vs. 61.3% of patients without baseline OVs; 29.6% vs. 64.3% of patients with baseline OVs). Achievement of SVR was significantly associated with reduced occurrence rates of de-novo OVs, hepatic decompensation and HCC. Compared to patients without SVR, patients with SVR had lower likelihoods of liver-related death at 10 years (20.6% vs. 10.3% of patients without baseline OVs; 50.5% vs. 21.8% of patients with baseline OVs). Conclusions: In patients with compensated HCV-related cirrhosis with or without OVs at baseline, SVR is associated with reduced disease progression and liver-related mortality.

KW - cirrhosis

KW - HCV

KW - multistate

KW - SVR

UR - http://www.scopus.com/inward/record.url?scp=84995488363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995488363&partnerID=8YFLogxK

U2 - 10.1111/liv.13156

DO - 10.1111/liv.13156

M3 - Article

VL - 36

SP - 1765

EP - 1773

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 12

ER -